PRNewsWire
14 Aug 2026, 14:00 UTC · 1d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The FDA granted Fast Track designation to Phanes Therapeutics' drug spevatamig for the treatment of advanced and metastatic biliary tract carcinoma (BTC). — Fast Track designation accelerates the regulatory review process, increasing the probability and speed of potential commercialization.
+0.60Phanes expanded its clinical trial collaboration with Merck to study spevatamig in combination with pembrolizumab for the first-line treatment of biliary tract carcinoma. — Partnering with a major pharmaceutical player like Merck validates the asset's potential and provides significant resource/distribution advantages.
+0.50Phanes completed enrollment in a Phase 2 clinical trial of spevatamig combined with chemotherapy for the first-line treatment of metastatic pancreatic ductal adenocarcinoma. — Completion of enrollment is a key milestone that brings the company closer to receiving clinical data that can drive valuation.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Spevatamig is a first-in-class bispecific antibody acting as an innate immunity enhancer (I2E), targeting claudin 18.2 and CD47. — Being 'first-in-class' suggests a potential monopoly or leadership position in a new therapeutic category if successful.
+0.30Which stocks this story touches
Expanding clinical collaboration to study combination therapy with pembrolizumab is a positive strategic development.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
6h ago
